WHAT WE DO FOR
WHAT WE DO FOR
WHAT WE DO FOR

PATIENTS

WHAT WE DO FOR PATIENTS

WEP Clinical helps patients and physicians obtain early access to medicines that are currently unavailable in their country. These can be investigational (Pre-Approval) drugs that are still in clinical trials, or commercialized (Post-Approval) drugs that are not yet available in all countries. Through our expertise and experience sourcing and distributing medicines worldwide, we provide a vital service that helps patients access treatments for rare diseases, cancer and other life-threatening or seriously debilitating conditions.

Learn More

SPONSORS

WHAT WE DO FOR SPONSORS

WEP Clinical partners with sponsors to set up and manage Expanded Access Programs (EAPs), Named Patient Programs (NPPs) and Product Commercialization. Our versatile service offering can be adapted to suit your company’s needs at any stage in the drug development, review or commercialization process. We provide end-to-end solutions including Project and Product Management, Global Regulatory Management, Real World Data (RWD) Collection, Warehousing and Distribution, Over-labelling and Product Commercialization.

Learn More

HOSPITALS

WHAT WE DO FOR HOSPITALS

WEP Clinical helps hospitals access medicines which are either unlicensed, not commercially available or facing shortage in their country. We utilize our validated global network to source drugs from around the world and help Healthcare Professionals (HCPs) obtain the special authorizations needed to import and supply directly to any hospital. We have dedicated country managers and in-house pharmacists, all with local language capabilities and all supported by an experienced operations team, to ensure your patients’ needs are met.

Learn More

PATIENTS

WHAT WE DO FOR PATIENTS

WEP Clinical helps patients and physicians obtain early access to medicines that are currently unavailable in their country. These can be investigational (Pre-Approval) drugs that are still in clinical trials, or commercialized (Post-Approval) drugs that are not yet available in all countries. Through our expertise and experience sourcing and distributing medicines worldwide, we provide a vital service that helps patients access treatments for rare diseases, cancer and other life-threatening or seriously debilitating conditions.

Learn More

SPONSORS

WHAT WE DO FOR SPONSORS

WEP Clinical partners with sponsors to set up and manage Expanded Access Programs (EAPs), Named Patient Programs (NPPs) and Product Commercialization. Our versatile service offering can be adapted to suit your company’s needs at any stage in the drug development, review or commercialization process. We provide end-to-end solutions including Project and Product Management, Global Regulatory Management, Real World Data (RWD) Collection, Warehousing and Distribution, Over-labelling and Product Commercialization.

Learn More

HOSPITALS

WHAT WE DO FOR HOSPITALS

WEP Clinical helps hospitals access medicines which are either unlicensed, not commercially available or facing shortage in their country. We utilize our validated global network to source drugs from around the world and help Healthcare Professionals (HCPs) obtain the special authorizations needed to import and supply directly to any hospital. We have dedicated country managers and in-house pharmacists, all with local language capabilities and all supported by an experienced operations team, to ensure your patients’ needs are met.

Learn More

OUR SERVICES

Icon made by Freepik from www.flaticon.com
Expanded Access Programs
More >
Icon made by Freepik from www.flaticon.com
Named Patient Programs
More >
Icon made by Freepik from www.flaticon.com
Product Commercialization
More >
Icon made by Freepik from www.flaticon.com
Hospital & Pharmacy Unlicensed Supply
More >
Icon made by Freepik from www.flaticon.com
Clinical Trial
Sourcing
More >
0
11+ Years of Experience
0
2000+ Unique Products Distributed
0
Distributed to over 120 countries

WEP Clinical possess all the necessary licenses to allow us to source, handle, store and distribute pharmaceutical drugs and controlled substances in the US, EU and ROW. All of our activities are conducted under the strict guidelines of GCP, GDP and GMP, and we have a robust set of SOPs that guide all company processes and procedures. We would be happy to provide further detail on this as requested.

TESTIMONIALS

“I’ve never experienced such an efficient, reliable, flexible, and respectful team that exudes commitment to our programs”

EAP Sponsor in the US

“You are so awesome! I wish all suppliers were this good. Thanks again”

Commercial Product Procurement Specialist

“It’s been a tremendous example of teamwork, the efforts of your company and ours, and I’m very grateful for your partnership.”

EAP Sponsor in the US

“I think it is important for your readers to know that WEP is superb to work with and make it easy to walk you through every step in the process.”

Hypersomnia Patient in the US

“Thank you for the update and your superb customer service. We do genuinely appreciate your willingness to try to keep a happy customer, and this will definitely help us to keep coming back with future orders. WEP has been a great vendor to work with and glad we were able to find you guys.”

Sr. Manager, Materials Management

“We have just referred your company, WEP, as the one that currently works best in terms of processes and importation of medicines. I wanted to let you know this because although we are very demanding, we also acknowledge when a company stands out of the crowd.”

Local Health Authority Representative

“We really think that you and your team are amazing with the customer service, deliverable, and quality. Please extend our appreciation to you and your team members you guys are awesome!”

Associate Project Manager, Comparator Program

Case Studies

View All Case Studies

A pharmaceutical company developing a new treatment for a rare neurodegenerative disease had to set very strict eligibility criteria for its clinical trials. […]

A leading pharmaceutical company wanted to distribute its approved product for the treatment of a rare congenital disease into new markets where it has not yet received regulatory approval. […]

A pharmaceutical company based in North America received EMA marketing approval for its bioequivalent product for an ultra-rare disease. […]